May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Serum Concentrations of Interleukin-6 and Metastasis From Uveal Melanoma
Author Affiliations & Notes
  • A. Lane
    Retina Service, Department of Ophthalmology, Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • C. L. Cubitt
    Clinical Trials Core,
    H. Lee Moffitt Cancer Center, Tampa, Florida
  • J. D. Yocum
    Retina Service, Department of Ophthalmology, Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • A. Chaglassian
    Retina Service, Department of Ophthalmology, Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • E. S. Gragoudas
    Retina Service, Department of Ophthalmology, Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • K. M. Egan
    Division of Cancer Prevention and Control,
    H. Lee Moffitt Cancer Center, Tampa, Florida
  • Footnotes
    Commercial Relationships  A. Lane, None; C.L. Cubitt, None; J.D. Yocum, None; A. Chaglassian, None; E.S. Gragoudas, None; K.M. Egan, None.
  • Footnotes
    Support  Massachusetts Lions Eye Research Fund
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 55. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Lane, C. L. Cubitt, J. D. Yocum, A. Chaglassian, E. S. Gragoudas, K. M. Egan; Serum Concentrations of Interleukin-6 and Metastasis From Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):55. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : . High circulating levels of interleukin-6 (IL-6), a pro-angiogenic cytokine involved in tumor growth and proliferation, have been associated with poor prognosis in metastatic cutaneous melanoma. We evaluated whether IL-6 concentrations measured in the serum are predictive of outcome in patients with melanoma of the uveal tract.

Methods: : . We evaluated 770 patients diagnosed with uveal tract melanoma and treated with proton therapy, who had contributed a blood sample at diagnosis or after irradiation. Vital status was ascertained through active follow-up, chart reviews, and a search of the Social Security Death Index. Median follow up among surviving patients was 6.5 years. Il-6 concentrations were measured using commercially available ELISA kits (R&D Systems, Inc., Minneapolis, MN) according to the manufacturer's instructions and intra-assay reliability was assessed in paired samples from sixteen patients (Pearson r=0.952; p<0.001). The association between circulating IL-6 concentrations and risk of melanoma-related mortality was evaluated in multivariate Cox regression models that included terms for tumor size, extrascleral invasion, anterior-most tumor margin and patient age.

Results: : . Serum concentrations of IL-6 were comparable in patients that developed metastasis (N=121; median: 1.91 pg/ml) and those that remained metastasis-free during the follow-up period (N=649; median: 1.94 pg/ml). Measurements of IL-6 were positively correlated with patient age (Pearson r = 0.22; P<0.001), but were independent of tumor-associated prognostic factors (not shown). Multivariate regression models failed to demonstrate any association of IL-6 with subsequent development of metastasis (P trend = 0.944).

Conclusions: : . These preliminary results suggest that serum IL-6 is not a useful biomaker of tumor aggressiveness in uveal melanoma.

Keywords: melanoma • cytokines/chemokines • clinical (human) or epidemiologic studies: risk factor assessment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×